BPC-157 Peptide (10MG)

This 2025 study in Pharmaceutics (Matek et al.) tested BPC 157 in a rat surgical model. In this model, the quadriceps muscle is cut away from its attachments on the femur and pelvis. Without treatment, the detached muscle does not reattach in rats, which leaves lasting gait problems and knee contracture.

Rats given BPC 157 in drinking water after surgery were compared with rats given plain water. Over 90 days, the researchers tracked walking pattern, motor function, contracture, muscle diameter, ultrasound and MRI findings, biomechanical measures and tissue histology.

Scope: This was an animal study in male rats. It did not test BPC 157 in people.

• Citation: Matek D, Matek I, Staresinic E, et al. Pharmaceutics. 2025;17(1):119.
• Animals: Male albino Wistar rats, 12–16 weeks old, 6 rats per group per time point
• Model: Surgical detachment of the quadriceps: complete for rectus femoris, partial for the vastus muscles
• Administration in the study: Oral. One dose was given by stomach tube 5 minutes after surgery, then the peptide was given in drinking water until the end of each interval.
• Comparison: Plain drinking water
• Time points: 1, 2, 3, 5, 7, 14, 21, 28, 60 and 90 days after surgery
• Authors' disclosure: No conflicts of interest declared

The authors asked whether BPC 157, given by mouth from the time of surgery, would change the course of a quadriceps detachment injury in rats. Specifically, they looked at reattachment of the muscle to bone and recovery of walking.

The group had previously reported BPC 157 studies in other rat musculoskeletal models, including myotendinous junction and tendon-to-bone injuries. This study extended that work to a muscle-to-bone model.

Under anesthesia, the rectus femoris was fully detached from the iliac bone and the vastus muscles were partially detached from the femur. Rats then received BPC 157 at 10 µg/kg or 10 ng/kg, or water as a control. The first dose was given by stomach tube 5 minutes after surgery, and the rest in drinking water. These are the amounts reported in the paper's rat protocol.

The researchers assessed:

• Function: Walking Recovery Index (WRI), Motor Function Index (MFI) and gait analysis
• Structure: Thigh muscle diameter, gross gap assessment, ultrasound and 1.5 T MRI
• Tissue: Light microscopy and collagen (Sirius red) staining at the muscle–bone junction

Walking and motor function: Control rats showed persistently impaired walking and permanent knee flexion. The authors reported that BPC 157-treated rats at both dose levels showed improved WRI and MFI scores and gait patterns at the time points assessed.

Contracture and muscle diameter: Leg contracture persisted in controls. The authors reported that it was eliminated in BPC 157-treated rats, and thigh muscle diameter was closer to normal than in controls.

Imaging: On ultrasound, the gap between the detached muscle and bone was smaller in treated rats from early time points onward. MRI and gross assessment were consistent with reattachment in treated rats, while a gap remained in controls.

Histology: By day 3, treated rats showed more mesenchymal cells and reactivation of the periosteum, the membrane covering bone. At 3 months, muscle fibers could be traced into newly formed bone at the reattachment site, with organized collagen.

The authors discussed several processes that may relate to their findings. These come from the histology in this study and from the group's earlier research:

• Periosteal reactivation and mesenchymal cell activity at the injury site
• Effects on blood vessels and the nitric oxide (NO) system, which the authors' group has described in prior BPC 157 studies
• Healing that began on both the muscle side and the bone side of the detachment

The study did not directly measure these pathways. The authors present them as interpretation.

• This was a single rat study with 6 animals per group at each time point, all male.
• The surgical model is specific to experimental quadriceps detachment. Results do not show effects in other injuries, other species or people.
• Most published BPC 157 research comes from the same research group, so independent replication by other laboratories is limited.
• The paper reports findings in rats only. It does not establish safety, dosing or effects for any other use.

In this rat model of quadriceps muscle-to-bone detachment, Matek et al. reported that oral BPC 157 was associated with reattachment of muscle to bone, less contracture, and better walking and motor scores than in water-treated controls over 90 days. Ultrasound, MRI and histology supported these findings. The authors called for further study of these mechanisms.

This summary is provided for research and educational purposes. Statements on this page have not been evaluated by the FDA. Research compounds offered on this site are for laboratory research use only. They are not intended for human or veterinary use, or to diagnose, treat, cure, mitigate or prevent any disease.